Floatz logo

Therapeutic Asset Ratings

615 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Everolimus
Colon Carcinoma
Fudan UniversityP2CCC (55)
Everolimus
Metastatic Malignant Neoplasm
Fudan UniversityP2CCC (55)
Iparomlimab
Epithelial Ovarian Cancer
Fudan UniversityP2CCC (55)
Pyrotinib
Metastatic Malignant Neoplasm In The Brain
Fudan UniversityP2CCC (55)
Pyrotinib
Triple-Negative Breast Carcinoma
Fudan UniversityP2CCC (55)
shr0302
Peripheral T-Cell Lymphoma, Not Otherwise Specified
Fudan UniversityP2CCC (55)
Tuvonralimab
Ovarian Carcinoma
Fudan UniversityP2CCC (55)
Rapamycin
Breast Carcinoma
Fudan UniversityP1CCC (55)
Alpha Tocopherol
Colorectal Cancer
Fudan UniversityP3CCC (54)
Fluzoparib
Breast Cancer
Fudan UniversityP3CCC (54)
Osimertinib
Minimal Residual Disease
Fudan UniversityP3CCC (54)
Famitinib
Pancreatic Neoplasm
Fudan UniversityP2CCC (54)
Imlunestrant
Breast Cancer
Fudan UniversityP2CCC (54)
Inno-206
Neoadjuvant Therapy
Fudan UniversityP2CCC (54)
Raltitrexed
Rectal Carcinoma
Fudan UniversityP2CCC (54)
9mw2821
Breast Neoplasm
Fudan UniversityP2CCC (53)
9mw2821
Hormone Receptor Negative Tumor
Fudan UniversityP2CCC (53)
9mw2821
Hormone Receptor Positive Tumor
Fudan UniversityP2CCC (53)
Adebelimab
Breast Neoplasm
Fudan UniversityP2CCC (53)
Adebelimab
Hormone Receptor Negative Tumor
Fudan UniversityP2CCC (53)
Adebelimab
Hormone Receptor Positive Tumor
Fudan UniversityP2CCC (53)
Adebrelimab
Advanced Pancreatic Carcinoma
Fudan UniversityP2CCC (53)
Adebrelimab
Brain Metastasases
Fudan UniversityP2CCC (53)
Adebrelimab
Castration-Resistant Prostate Carcinoma
Fudan UniversityP2CCC (53)
Adebrelimab
Her2-Receptor Negative Breast Cancer
Fudan UniversityP2CCC (53)
Showing 176 to 200 of 615 assets
PreviousPage 8 of 25Next